We have previously demonstrated that a subset of SCLC cells that express high levels of BCL-2 are sensitive to venetoclax monotherapy in in vitro and in vivo mouse models of SCLC, including PDXs [13]. Here, BCL2 is linked to small cell lung carcinoma.